Search results
Complete CytomX Therapeutics Inc. stock information by Barron's. View real-time CTMX stock price and news, along with industry-best analysis.
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.
4 days ago · 6 equities research analysts have issued 1 year target prices for CytomX Therapeutics' stock. Their CTMX share price targets range from $3.50 to $8.00. On average, they predict the company's stock price to reach $5.77 in the next year. This suggests a possible upside of 337.3% from the stock's current price. View analysts price targets for CTMX ...
May 1, 2024 · CytomX Therapeutics (CTMX) stock surges as it fast-tracks Phase 1a data release for CX-904, a bispecific antibody developed with Amgen (AMGN). Read more here.
May 9, 2024 · CTMX stock is down 42.7% as of Thursday morning but is still up 41.7% since the start of the year. Investors looking for more of the most recent stock market stories are in luck!
May 1, 2024 · CTMX Stock Market Movement Today That earnings update has investors excited and with that comes heavy trading of CTMX stock. That has more than 126 million shares changing hands as of this writing.
See the company profile for CytomX Therapeutics, Inc. (CTMX) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives ...
